Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other hematologic neoplasm 1Myeloid 1

Conditions

Primary Myelofibrosis 1Myeloproliferative Disorders 1Myelodysplastic-Myeloproliferative Diseases 1Myelodysplastic Syndromes 1Leukemia, Myelomonocytic, Chronic 1Leukemia, Myeloid, Acute 1Leukemia, Myelogenous, Chronic, BCR-ABL Positive 1Leukemia 1Blast Crisis 1Anemia, Refractory, with Excess of Blasts 1Anemia, Refractory 1

Interventions

Cyclophosphamide 59fludarabine phosphate 53Peripheral Blood Stem Cell Transplantation 43Tacrolimus 40Mycophenolic Acid 36Busulfan 33Whole-Body Irradiation 32Antilymphocyte Serum 28Cyclosporine 27Methotrexate 25fludarabine 19Filgrastim 18Melphalan 17Radiotherapy 15Methylprednisolone 13Etoposide 12Cord Blood Stem Cell Transplantation 12thymoglobulin 11Sirolimus 11ruxolitinib 10Flow Cytometry 10Psychiatric Rehabilitation 9Azacitidine 9Stem Cell Transplantation 7Granulocyte Colony-Stimulating Factor 7Decitabine 7Therapeutics 6Imatinib Mesylate 6Cytarabine 6Cyclosporins 6

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Primary Myelofibrosis × vatalanib × Other hematologic neoplasm × Clear all
NCT00088231 2012-01-20

PTK 787 and Gleevec in Patients With AML, AMM, and CML-BP

M.D. Anderson Cancer Center

Phase 1/2 Completed
9 enrolled
MyeloidOther hematologic neoplasm

Blast Crisis, Leukemia, Myelogenous, Chronic, BCR-ABL Positive, Leukemia, Myeloid, Acute, Primary Myelofibrosis

Data powered by HemOnc (CC BY 4.0) Colophon âš¡